GlassScriptPhysician profile
Steven D Belen
NPI 1679564843
$4,796.29
in general payments reported to CMS, 2019-2025
28 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $59.89 · 2021: $164 · 2022: $1,292 · 2023: $1,447 · 2024: $684 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944 · Consulting Fee: $15.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.66 |
| Consulting Fee | $15.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $684.21 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $481.28 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $461.12 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $430.69 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $429.82 | 2022-2025 | Lifevest |
| Pfizer INC. | $319.72 | 2019-2025 | |
| Amgen INC. | $259.57 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.13 | 2023-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $186.34 | 2023-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $174.24 | 2021-2024 | Brilinta, Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $142.59 | 2022-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $139.68 | 2022-2024 | Opsumit, Uptravi |
| Kestra Medical Technology Services, INC. | $101.45 | 2023-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $101.02 | 2023-2024 | |
| Baxter Healthcare | $92.16 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $90.37 | 2022-2025 | Ecc Solutions |
| Boston Scientific Corporation | $85.81 | 2021-2025 | Watchman Access System |
| Edwards Lifesciences Corporation | $83.43 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi-Aventis U.S. LLC | $74.94 | 2019-2022 | |
| Abbott Laboratories | $48.98 | 2025 | Amplatzer Amulet, Cardiomems |
| Kiniksa Pharmaceuticals International, Plc | $42.22 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $27.09 | 2024 | Optimizer |
| Vivaquant INC, Dba Rhythm Express | $26.96 | 2024-2025 | Rhythm Express, Rhythm Express |
| Medtronic, INC. | $26.49 | 2021-2022 | |
| Abiomed | $25.68 | 2025 | |
| Heartflow, INC. | $23.05 | 2023 | Ffrct |
| Bridgebio Pharma, INC. | $22.68 | 2025 | Attruby |
| Bardy Diagnostics, INC. | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Belen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.